208 mechanistic studies (e.g. host–microbe co-culture systems) that could provide functional confirmation of relevant pathophysiological gene–bacteria interactions and serve as a resource for rational selection of therapeutic targets in IBD. This study presents a large-scale, comprehensive landscape of intestinal host–microbe interactions in IBD that could aid in guiding drug development and provide a rationale for microbiota-targeted therapy as a strategy to control disease course. Future studies are warranted to focus on the integration of host–microbe interaction modules in prospective clinical trials investigating their utility for predicting disease course and responsiveness to treatment and for stratifying patients to facilitate therapeutic decision-making. Chapter 6
RkJQdWJsaXNoZXIy MjY0ODMw